Selective inhibitor of p38 MAPK (IC50
values are 50 and 500 nM for SAPK2a/p38 and SAPK2b/p38β
2 respectively). Displays 100-500-fold selectivity over LCK, GSK-3β
. Shown to inhibit IL-2-induced T cell proliferation, cyclooxygenase-1 and -2, and thromboxane synthase. Enhances clonal growth of skin epithelial progenitor cells; stimulates neural stem cell (NSC) proliferation. Essential component of medium for maintaining stem cells in naive pluripotent state. Part of the MAPK Cascade Inhibitor Tocriset™
and MAPK Inhibitor Tocriset™
. Water-soluble salt SB 203580 hydrochloride
(Cat. No. 1402) also available.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of GlaxoSmithKline
Other Product-Specific Information:
Specificity and mechanism of action of some commonly used protein kinase inhibitors.
Davies et al.
Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059.
Borsch-Haubold et al.
Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen on a thromboxane analogue.
Saklatvala et al.
Inhibitors of p38 mitogen-activated protein kinase enhance proliferation of mouse neural stem cells.
Sato et al.
Derivation of novel human ground state naive pluripotent stem cells.
Gafni et al.
The citations listed below are publications that use Tocris products. Selected citations for SB 203580 include:
Showing Results 1 - 10 of 61